Interpatient Pharmacokinetic and Pharmacodynamic Variability of Carrier-Mediated Anticancer Agents

被引：55

作者：

Caron, W. P. ^{[1
]}

Song, G. ^{[1
]}

Kumar, P. ^{[1
]}

Rawal, S. ^{[1
]}

Zamboni, W. C. ^{[1
,2
,3
,4
,5
]}

机构：

[1] Univ N Carolina, Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC 27599 USA

[2] Univ N Carolina, Inst Pharmacogenom & Individualized Therapy, Chapel Hill, NC USA

[3] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA

[4] Univ N Carolina, Carolina Ctr Canc Nanotechnol Excellence, Chapel Hill, NC USA

[5] Univ N Carolina, Biomed Innovat Network, Chapel Hill, NC USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2012年 / 91卷 / 05期

关键词：

PEGYLATED LIPOSOMAL DOXORUBICIN; TISSUE DISTRIBUTION; CKD-602; S-CKD602; RENAL TOXICITY; SURFACE-CHARGE; TUMOR; CISPLATIN; CANCER; BIODISTRIBUTION; NANOPARTICLE;

D O I：

10.1038/clpt.2012.12

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Major advances in the field of carrier-mediated agents (CMAs) have revolutionized drug delivery capabilities over the past decade. While providing numerous advantages over their small-molecule counterparts (solubility, duration of exposure, and delivery to the site of action are higher), these agents display substantial variability in systemic clearance (CL) and distribution, tumor delivery, and pharmacologic effects. This review provides an overview of factors that affect the pharmacokinetics (PK) and pharmacodynamics (PD) of CMAs in preclinical models and patients.

引用

收藏

页码：802 / 812

页数：11

相关论文

共 64 条

[1]

Nanomedicines for overcoming biological barriers [J].

Alonso, MJ .

BIOMEDICINE & PHARMACOTHERAPY, 2004, 58 (03) :168-172

[2]

[Anonymous], 2006, IRINOTECAN HYDROCHLO

[3]

The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin [J].

Berry, G ;

Billingham, M ;

Alderman, E ;

Richardson, P ;

Torti, F ;

Lum, B ;

Patek, A ;

Martin, FJ .

ANNALS OF ONCOLOGY, 1998, 9 (07) :711-716

[4]

SPECIFIC TARGETING WITH POLY(ETHYLENE GLYCOL)-MODIFIED LIPOSOMES - COUPLING OF HOMING DEVICES TO THE ENDS OF THE POLYMERIC CHAINS COMBINES EFFECTIVE TARGET BINDING WITH LONG CIRCULATION TIMES [J].

BLUME, G ;

CEVC, G ;

CROMMELIN, MDJA ;

BAKKERWOUDENBERG, IAJM ;

KLUFT, C ;

STORM, G .

BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1149 (01) :180-184

[5]

Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel [J].

Briasoulis, E ;

Karavasilis, V ;

Tzamakou, E ;

Rammou, D ;

Soulti, K ;

Piperidou, C ;

Pavlidis, N .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (05) :452-457

[6]

Cellular function of the mononuclear phagocyte system (MPS) as a phenotypic probe for pegylated liposomal doxorubicin (PLD) pharmacokinetics (PK) in patients with recurrent ovarian cancer. [J].

Caron, W. P. ;

Lay, J. C. ;

Fong, A. M. ;

La-Beck, N. M. ;

Newman, S. E. ;

Clarke-Pearson, D. L. ;

Brewster, W. R. ;

Van Le, L. ;

Bae-Jump, V. L. ;

Gehrig, P. A. ;

Zamboni, W. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[7]

From conventional to stealth liposomes: a new frontier in cancer chemotherapy [J].

Cattel, L ;

Ceruti, M ;

Dosio, F .

JOURNAL OF CHEMOTHERAPY, 2004, 16 :94-97

[8]

Rate of biodistribution of STEALTH® liposomes to tumor and skin:: influence of liposome diameter and implications for toxicity and therapeutic activity [J].

Charrois, GJR ;

Allen, TM .

BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2003, 1609 (01) :102-108

[9]

Devarajan P, 2004, ANTICANCER RES, V24, P2193

[10]

Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution [J].

Dobrovolskaia, Marina A. ;

Aggarwal, Parag ;

Hall, Jennifer B. ;

McNeil, Scott E. .

MOLECULAR PHARMACEUTICS, 2008, 5 (04) :487-495

← 1 2 3 4 5 6 7 →